A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
| Clinical Pharmacology |
 DANIEL HACKAM, MD, FRCPC, PhD, BSc, Associate Professor Daniel Gidon Hackam BSc MD PhD FRCPC is an Assistant Professor in the Divisions of Clinical Pharmacology and Clinical Neurological Sciences and the Department of Epidemiology and Biostatistics. Dr. Hackam is a scientist at the Robarts Research Institute, Clinical Trials Research Group and Vascular Biology Group. His research is diverse and focuses on the pharmacoepidemiology of atherosclerosis, risk factor assessment, and translation of novel findings from basic science to clinical trials. His background includes training in internal medicine, clinical pharmacology, cardiac rehabilitation, clinical epidemiology and health services research. Dr. Hackam’s publications have appeared in The Lancet, JAMA, Circulation, Stroke, Neurology, American Journal of Medicine, CMAJ, BMJ and in numerous research forums and symposia. Keywords: Atherosclerosis prevention and therapy Meta-analysis, Development of new methodologies Pharmacoepidemiology including adverse drug events Systematic reviews, Development of new methodologies |
| Critical Care Medicine |
 WAEL HADDARA, MD, BSc. Pharm , FRCPC, Associate Professor, Chair, Division of Critical Care Dr Haddara is the Chief of Critical Care at London Health Sciences Center and Chair of the Division of Critical Care Medicine. He previously served as the Medical Director of the Medical/Surgical ICU at University Hospital and was the inaugural Physician Lead for the Critical Care Outreach Team. He holds a Masters in Medical Education from Dundee University and has been actively involved with the Center of Education, Research and Innovation (CERI) at Schulich School of Medicine. His program of research examines core ideas and values in Medicine that are often thought of as timeless or intrinsic such as interprofessional collaboration and altruism. He draws on critical research methods such as critical discourse analysis and genealogical analysis to uncover tensions within those concepts. Dr Haddara holds Royal College certification in Internal Medicine, Endocrinology and Intensive Care. He previously trained and worked as a pharmacist, and continues to hold registration (Register B) with the Ontario College of Pharmacists. London has been his home since 1999. Keywords: Altruism Endocrine aspects of critical illness Medical education Professionalism |
| Endocrinology and Metabolism |
 ROBERT HEGELE, MD, FRCPC, FACP, FAHA, FCAHS, Distinguished University ProfessorRob Hegele is Distinguished University Professor of Medicine and Biochemistry, Western University, and Director of London Regional Genomics Centre at Robarts Research Institute. He holds the Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Chair in Human Genetics and the Blackburn Chair in Cardiovascular Research. He cares for >2500 patients in his lipid clinic at University Hospital. His laboratory discovered the genes that cause >25 human diseases. He was among the first in the world to use five medications that are now routinely prescribed to treat dyslipidemia or diabetes. He has published >925 papers that have been cited >80,000 times (Google Scholar; h-index 131), and is in the top 1% of highly cited scientists in the world. The website Expertscape.com in 2023 ranked him #1 globally in the area of “hypertriglyceridemia”, #2 for “disorders of lipid metabolism” and #3 for “hypercholesterolemia”. He received the 2019 American Heart Association Lyman Duff Award, the 2020 FH Foundation Pioneer Award, and the 2024 Virgil Brown Distinguished Achievement Award from the US National Lipid Association. He has co-authored many clinical practice guidelines for cholesterol, blood pressure and diabetes. He has trained numerous physicians, medical students and graduate students. Keywords: Association/linkage analysis Atherosclerosis Bioinformatic analysis Cloning Coronary heart disease DNA sequencing Dyslipidemia Genetics Insulin resistance Lipids/lipoproteins Metabolic syndrome Metabolism MRI Mutation identification Next generation sequencing Obesity PCR Type 2 diabetes Whole exome sequencing Whole genome sequencing |
| Endocrinology and Metabolism |
 DAVID HILL, DPhil, FCAHS; Scientific Director Lawson Health Research Institute, Professor Departments of Medicine, Physiology & Pharmacology, and Paediatrics; Integrated Vice President, Research for London Health Sciences Centre and St. Joseph's Health Care London
Dr. Hill's research centres on the mechanisms of physiological and pathological plasticity of new insulin-producing beta cells in the pancreas as a strategy for the reversal of diabetes. He has a basic science laboratory using mouse models of beta cell plasticity such as pregnancy and induced diabetes. Projects include the mechanisms whereby low or high birth weight result in an increased risk of diabetes in later life, and the ways in which environmental factors, such as nutrition, might trigger or protect against diabetes. He is also a member of the DALI pan-European clinical trials network focused on the early identification and prevention of gestational diabetes. Dr Hill has published over 300 original papers and review articles and has an H-factor in the mid-60’s. He is also closely involved in advocacy for health research in Canada and is a Member of the Board of Directors of both Research Canada and Health Care Can, in addition to being co-Chair of the Ontario Hospital Association Research and Innovation Committee. Keywords: Clinical trials Development of the pancreas Developmental origins of adult disease Diabetes Gestational diabetes Pancreatic Islets Peptide growth factors Pregnancy |
| Nephrology |
 ANDREW HOUSE, MD, FRCPC, HBSc, MSc, Professor, Chair, Division of Nephrology Dr. Andrew House is a Professor in the Faculty of Medicine at the Schulich School of Medicine & Dentistry, Western University, and is currently the Chair of the Western University Division of Nephrology. He did his training in Physiology & Pharmacology at Western before his MD and specialist training at the University of Ottawa, and Masters in Epidemiology & Biostatistics at Western. As a trained clinical epidemiologist and nephrologist, Dr. House focuses on the design and analysis of clinical trials in AKI, CKD, hemodialysis and transplantation. In 2007 he completed a six month sabbatical in Vicenza, Italy, where he developed expertise in Critical Care Nephrology and Cardiorenal Syndromes. He collaborates on research into drug metabolism in varying degrees of chronic kidney disease. He was a member of the ADQI consensus conferences on Cardio-Renal Syndromes held in Venice in 2008 and 2012, and was a Distinguished Faculty at a symposium on Cardio-Renal Syndromes at the American Society of Nephrology Annual Meeting in San Diego, 2009, a symposium on Heart Failure Syndromes at the American Thoracic Society Annual Meeting in New Orleans, 2010, and the Vicenza Course on Hemodialysis in Vicenza, Italy, 2011. He was co-Chair of the international KDIGO Conference on Congestive Heart Failure in May 2017, and invited lecturer on Heart Failure in Chronic Kidney Disease at the 7th Annual Nephrology Summit in Kochin and Hyderabad, India in September 2017. More recently, he helped establish the Adult Tuberous Sclerosis Clinic at LHSC, which he directs, and has turned his research sites on understanding mechanisms and treatments for this complex syndrome. Keywords: Cardio-renal syndromes Cardiovascular disease Clinical trials Hemodialysis Homocysteine Kidney diseases Transplantation Tuberous Sclerosis Complex |
| Endocrinology and Metabolism |
 Dr. IRENE MARY HRAMIAK, MD, FRCP(C), MACP
Professor - Department of Medicine Department of Medicine Site Chief, St. Joseph's Hospital Irene M. Hramiak, MD, FRCP(C), MACP is a Professor of Medicine, Western University, London, ON. She is the current Department of Medicine Site Chief at St. Joseph’s Hospital. Dr. Hramiak practices Endocrinology at St. Joseph’s Hospital in London, Ontario, with a strong clinical interest in Type 1 and Type 2 diabetes mellitus. Dr. Hramiak has held peer reviewed funding from JDRF, CDA, and the NIH since 1983; she was a co-investigator in the DCCT (1983-2000), for which she was awarded the Charles H. Best Award for distinguished service by the American Diabetes Association in 1993. In 2016, she was awarded the Canadian Diabetes Association’s Gerald S Wong Service Award. She has been a Principle Investigator in many cardiovascular outcome trials in Type 2 diabetes mellitus, including: ACCORD, ORIGIN, TECOS, LEADER, SUSTAIN, REWIND, and DECLARE-TIMI 58. Dr. Hramiak was the Principle Investigator at Western University for the JDRF Ontario trial network. She has been a Principle Investigator for REMOVAL and other trials investigating benefits of new therapies in Type 1 Diabetes. Dr. Hramiak has been recognized by ACP with a Mastership for Academic Excellence in 2020. Western University has awarded her the Alumni of Distinction Award in 2021. Dr. Hramiak serves as an external advisor to many groups and pharmaceutical companies with regards to diabetes and obesity. Keywords: Diabetes Obesity |
| Hematology |
 CYRUS HSIA, MD, FRCPC, HBSc, Associate Professor I completed by undergraduate degrees in Mathematics and Human Biology at the University of Toronto, my medical school training at the University of Western Ontario (Schulich School of Medicine & Dentistry), my residency in Internal Medicine and fellowship training in Hematology at UWO as well. Currently, I am an associate professor at Western University and associate medical director of the blood transfusion laboratory at the London Health Sciences Centre. My research interests are mainly in the field of transfusion medicine in the safe and appropriate utilization of blood and blood products as it relates to hematologic diseases. Specific clinical areas of interest include ITP, MDS, iron deficiency and overload. Keywords: Anemia Blood Blood products Iron Iron deficiency Iron overload ITP MDS Myelodysplasia Transfusion medicine |
| Nephrology |
 SHIH-HAN SUSAN HUANG, MD, FRCPC, Associate Professor
I have completed my medical degree at the University of Ottawa in 2005 and finished the specialty/subspecialty trainings (internal medicine and nephrology) in 2010 at Western University. In addition, I have successfully completed the Certificate in the Department of Epidemiology and Biostatistics in 2012. In 2015, I received my PhD degree through the Department of Medical Biophysics with the support of numerous research awards, including the Canadian Institute of Health Research (CIHR) Fellowship Award for Health Professional and the Vanier CGS award. My doctoral research was on dialysis adequacy using a new marker, cystatin C. I currently have over 50 publications and over 10 research projects ongoing. My research interests include medical biophysics, TTP and extracoporeal therapies. Keywords: Cystatin C Glomerular nephritis Hemodialysis Plasmapheresis |
